SCHEMBL2696012

SCHEMBL2696012

CC(=O)Nc1ccc(Nc2cc(N(C)c3cccc4[nH]ccc34)c(C(N)=O)cn2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 1/20 0.42
▸ SIRT2 Q8IXJ6 1/20 0.42
▸ MAPK8 P45983 1/20 0.39
▸ PIP4K2C Q8TBX8 1/20 0.39
▸ PARP1 P09874 2/20 0.39
▸ DHODH Q02127 2/20 0.39
▸ JAK3 P52333 4/20 0.38
▸ MELK Q14680 1/20 0.38
▸ HPGDS O60760 2/20 0.37
▸ DHPS P49366 1/20 0.37
▸ SYK P43405 2/20 0.37
▸ MAPK9 P45984 1/20 0.37
▸ MAPK10 P53779 1/20 0.37
▸ JAK2 O60674 2/20 0.37
▸ JAK1 P23458 2/20 0.37
▸ TYK2 P29597 2/20 0.37
▸ IRAK4 Q9NWZ3 2/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ PIK3C3 Q8NEB9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2695525 0.90 CSF1R (0.41) CSF1RPARP1JAK3SYKMAPK9
SCHEMBL2692967 0.89 SYK (0.42) CSF1RSIRT2JAK3HPGDSSYK
SCHEMBL2695612 0.88 CSF1R (0.44) CSF1RSYKIRAK4
SCHEMBL2693114 0.87 CSF1R (0.42) CSF1RPARP1SYKJAK2
SCHEMBL2695887 0.86 CSF1R (0.39) CSF1RJAK3HPGDSSYKMAPK9
SCHEMBL2696726 0.86 SYK (0.44) CSF1RSIRT2JAK3SYKMAPK9
SCHEMBL2693187 0.85 SIRT2 (0.42) CSF1RSIRT2MAPK8PARP1DHODH
SCHEMBL2695026 0.85 ABL1 (0.39) CSF1RJAK3SYKMAPK9MAPK10
SCHEMBL2693148 0.85 SYK (0.45) CSF1RJAK3HPGDSSYKMAPK9
SCHEMBL2695179 0.85 ABL1 (0.53) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 — — US claimed
EP-2635557-A2 NICOTINAMIDES AS JAK KINASE MODULATORS Portola Pharmaceuticals, Inc. (US) 2013-09-11 — — EP claimed
WO-2012061428-A2 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 — — WO claimed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 — — US claimed
EP-2975027-A1 NICOTINAMIDES AS JAK KINASE MODULATORS Portola Pharmaceuticals, Inc. (US) 2016-01-20 — — EP disclosed
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 — — US disclosed
US-9102625-B2 Nicotinamides as JAK kinase modulators PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-11 — — US disclosed
EP-2635557-A2 NICOTINAMIDES AS JAK KINASE MODULATORS Portola Pharmaceuticals, Inc. (US) 2013-09-11 — — EP disclosed
WO-2012061428-A2 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 — — WO disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK CSF1R 1106/4885SIRT2 141/4885MAPK8 398/4885
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK CSF1R 1106/4885SIRT2 141/4885MAPK8 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback